Cannabis Law Report

SEPTEMBER 24, 2019

Here is the BBC report and below you will find the full press release from GW Pharmaceuticals. T he EU has approved for the first time the use of a medicinal cannabis product aimed at patients with two rare, but severe, forms of childhood epilepsy. What about other medical cannabis products? ” Source BBC: [link]. PDF Version.

Pharmaceutical 55

Pharmaceutical Epilepsy Research and Development Medicine 55

Cannabis Law Report

DECEMBER 3, 2021

–(BUSINESS WIRE)– $MRNS #MarinusPharma — Marinus Pharmaceuticals, Inc. Chief Executive Officer of Marinus Pharmaceuticals. “We Chief Executive Officer of Marinus Pharmaceuticals. “We Webcast to be held Monday, December 6 at 1:00 p.m. ET (12:00 p.m. RADNOR, Pa.–(BUSINESS

Epilepsy 52

Epilepsy Pharmaceutical Data Clinical Trials 52

SpeedWeed

MARCH 13, 2021

Almost 25% of patients with Parkinson’s disease reported that they had used cannabis in the prior six months in a survey from the Parkinson’s Foundation. Parkinson’s disease patients typically use pharmaceutical medications to treat their condition with varying degrees of success. More Than 1,000 PD Patients Surveyed.

Patients 52

Patients Treatment Therapy Sleep 52

Cannabis Law Report

FEBRUARY 1, 2022

New softgel capsule products further expand ZYUS’ medical cannabinoid offerings and provide patients a precise method for dosing. The two Zylem™ Softgel Capsule products each have their own unique colour to provide patients with an easy way to identify and distinguish between ZYUS softgel capsule formulations.

Cannabinoids 52

Cannabinoids Patients Research and Development Media 52

Cannabis Law Report

JUNE 28, 2021

Pharmaceutical and Medical Cannabis Leaders Zambon GmbH and Adven GmbH will Drive Medical Cannabis Supporting Treatments for Neurological Therapies. The aim of the agreement is to make medical cannabis treatments available to patients, with an initial focus on neurological therapies. The market for medical cannabis in Germany.

Access 105

Access Research and Development Pharmaceutical Therapy 105

Cannabis Law Report

NOVEMBER 17, 2021

. (“ZYUS”), a Canadian-based life sciences company leading scientific research and development in phyto-therapeutics, announced today that the company has launched a new THC-dominant medical cannabinoid formulation, Zylem™ 20:1, for direct sales and distribution to registered medical patients across Canada.

Cannabinoids 52

Cannabinoids Patients Research and Development Extraction 52

Cannabis Law Report

NOVEMBER 18, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its investment company Oravax Medical Inc. Oravax”), partially owned with its majority partner Oramed Pharmaceuticals Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Business Chronic Pain 52

Cannabis Law Report

JANUARY 5, 2022

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced that the U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. 2 Goates et al. 4 [link].

Pharmaceutical 52

Pharmaceutical Clinical Trials Therapy Treatment 52

CannaMD

FEBRUARY 19, 2020

Post-traumatic stress disorder (PTSD) is a condition most often associated with military veterans, but it is not confined to wartime experiences. And in recent years, a spate of new research has added scientific credibility to the success stories of patients who have used medical marijuana to relieve their symptoms.

CBD 92

CBD Pharmaceutical Research and Development Conditions 92

FloridaMarijuana.net

AUGUST 15, 2018

Living with PTSD, no matter the underlying cause of the trauma, can be extremely difficult for patients and their loved ones. The stress that results from traumatic events precipitates a spectrum of psycho-emotional and physiopathological outcomes. Trauma is common in women; five out of ten women experience a traumatic event.

Treatment 182

Treatment Marijuana Research and Development Therapy 182

NORML

JANUARY 24, 2019

It seeks to redefine allowed dosage limitations and formulations, and expand patient access and reduce patient cost by adding nurse practitioners and physician assistants to the list of those authorized to issue written certifications to patients. Marijuana policy should be evidence based.

Policy 160

Policy Patients Education Legislation 160

Cannabis Law Report

NOVEMBER 16, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical stage pharmaceutical company committed to extending healthy lifespan by delaying aging, announced today that it has received U.S. About MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals, Inc. 646) 421-9523.

Pharmaceutical 52

Pharmaceutical Clinical Trials Research and Development Therapy 52

Puff Puff Post

MARCH 10, 2020

SOURCE InMed Pharmaceuticals Inc. InMed has conducted preclinical pharmacology studies that suggest CBN in INM-755 may help relieve hallmark EB symptoms, including inflammation and pain, as well potentially restore the integrity of the skin in a subset of EB Simplex patients.

Clinical Trials 40

Clinical Trials Pharmaceutical Research and Development Cannabinoids 40

Cannabis Law Report

DECEMBER 29, 2021

BALTIMORE–(BUSINESS WIRE)– MyMD Pharmaceuticals, Inc. Nasdaq: MYMD) (“MyMD” or “the Company”), a clinical-stage pharmaceutical company committed to extending healthy lifespan, announced today that its investment company Oravax Medical Inc. Oravax”), partially owned with its majority partner Oramed Pharmaceuticals Inc.

Pharmaceutical 52

Pharmaceutical Clinical Trials Chronic Pain CBD 52

Cannabis Law Report

JUNE 16, 2021

Both parties to this new relationship are committed to excellence in clinical research and patient access to psychedelic medicine with a focus on naturally derived psilocybin. This engagement will build on the strong foundation on Santé, having treated more than 10,000 patients since 2014 under a real-world data protocol.

Clinical Trials 104

Clinical Trials Therapy Research and Development Events 104

Project CBD

MAY 3, 2023

Dr. Goldstein has treated thousands of patients with medical cannabis. CannMed: For what conditions do you think CBG has the most promise? Psoriasis is a well-known condition where people get not only joint pain but they also get these thick red patches and scales on their skin. It can be a very difficult condition.

Cannabinoids 209

Cannabinoids Sleep Clinical Trials CBD 209

Cannabis Law Report

JULY 19, 2021

The data from the study is expected to be embedded into the RYAH MD platform, with the goal of enabling healthcare professionals to administer THC, CBD and terpenes in milliliters, which are then expected to automatically be converted into milligrams to allow for a customized, targeted patient inhalation session. billion by 2027.

Therapy 76

Therapy Data Research and Development Events 76

CannaTech

APRIL 1, 2020

When I was at Pharmacy School at Sydney University, more than 20 years ago, we learned the pharmaceutical and clinical sciences ranging from the design, synthesis, formulation, dispensing and testing of drugs and the clinical and social aspects of pharmacy. And most especially in these times, cannabis is used effectively to treat anxiety.

Supply Chain 98

Supply Chain Chronic Pain Pharmaceutical Patients 98

Veriheal

SEPTEMBER 22, 2021

If the proposal — which was sponsored by Rules Committee Chairman Bill Rabon (R) — is enacted into law, patients who are diagnosed with a “debilitating medical condition” could legally gain access to medical cannabis in North Carolina. Home cannabis cultivation, on the other hand, would be forbidden.

Legalization 111

Legalization Patients Cultivation Legislation 111

Cannabis Law Report

JUNE 1, 2021

The initial shipment is designated to be used by the Clinic in a pilot run in preparation for the previously announced study , based out of the United Kingdom, on the safety and efficacy of cannabis and hemp for the treatment of patients suffering from chronic pain. billion, servicing nearly 340,000 active patients.

Clinical Trials 89

Clinical Trials Chronic Pain Data Research and Development 89

Cannabis Law Report

JUNE 23, 2021

Medicann is a premier cannabis-specialized clinic, providing patients with access to local specialist doctors and pharmacists that have experience prescribing cannabis-based medication. billion, servicing nearly 340,000 active patients. In 2019, the island’s economy grew by 2.1% in real terms to £4.97 to reach 3.2

Programs 100

Programs Data Events Collective 100

Veriheal

JULY 28, 2021

Not only could North Carolina’s medical cannabis bill assist cancer patients who suffer from pain and nausea but also, people with a broad spectrum of diseases and illnesses. The bill, which was approved by the majority of judiciary committee members, would develop a patient, manufacturing, licensing, and sales system for the plant’s use.

Seed-To-Sale 59

Seed-To-Sale Research and Development Pharmaceutical Conditions 59

Cannabis Law Report

AUGUST 2, 2021

OTCQB: SPRCY ) a specialty, clinical-stage pharmaceutical company focusing on the development of cannabinoid-based treatments, today announced positive top-line results for its proprietary compound, SCI-160 in a controlled pre-clinical trial on neuropathic and post-operative pain. TEL AVIV, Israel , Aug. ” About The Study.

Research and Development 105

Research and Development Clinical Trials Treatment Pharmaceutical 105

The Joint Blog

JUNE 2, 2020

According to a new study published in the European Journal of Pain, delivering a precise doses of THC via a specialized inhaler is associated with pain mitigation in patients with neuropathy and other complex pain conditions. Adverse events were mostly mild and resolved spontaneously. 9 -THC: 0.5mg, 1mg, or a placebo. ?

Chronic Pain 58

Chronic Pain Clinical Trials Safety Marijuana 58

Veriheal

MARCH 18, 2021

Unfortunately, both of these conditions result in cognitive decline and suffer from a lack of effective treatment. The team made use of a “cross-species” approach in order to deepen the understanding of Alzheimer’s disease as well as on the feline cognitive decline, thus benefiting “patients of all species”. Why Aging Cats?

CBD 95

CBD Research and Development Pets Treatment 95

Cannabis Law Report

OCTOBER 6, 2021

Flora Pharma will seek to identify scientific gaps in the cannabis industry and ultimately work to translate that to pharmaceutical cannabis products backed by data. MIAMI & TORONTO–(BUSINESS WIRE)–Flora Growth Corp.

Clinical Trials 52

Clinical Trials Research and Development Pharmaceutical Events 52

Cannabis Law Report

FEBRUARY 3, 2022

Nimbus Health is a privately owned, licensed pharmaceutical wholesaler from Germany focusing on medical cannabis in Germany. The acquisition will allow Dr. Reddy’s to build on Nimbus Health’s strengths and introduce medical cannabis-based medicines as a promising treatment option for patients. About Nimbus Health GmbH.

Pharmaceutical 52

Pharmaceutical Events Patients Medicine 52

Cannabis Law Report

NOVEMBER 23, 2019

for the production R&D of pharmaceutical grade standardised cannabis. Here the company shares their evolution with Health Europa, exploring the production of pharmaceutical grade standardised cannabis. KANNABEIRA® is a project and a registered trademark under the company Green Donation, Ltd. KANNABEIRA and standardised cannabis.

Pharmaceutical 45

Pharmaceutical Research and Development Cultivation Environment 45

Cannabis Law Report

NOVEMBER 9, 2021

Experienced Cannabis Executive, Registered Pharmacist and European Patent Attorney to Lead Pharmaceutical Strategy & Operations, Corporate Quality Management, Legal & Regulatory Affairs. She will work closely with Akanda’s EU GMP processing and distribution partner Cantourage GmbH, based in Germany. . About Akanda Corp.

Pharmaceutical 52

Pharmaceutical Seed-To-Sale Supply Chain Events 52

NORML

FEBRUARY 1, 2019

And officials in San Francisco, California are considering a proposal to allow marijuana to be socially consumed and sold at temporary events. Senate Bill 19-013 would permit physicians to recommend cannabis therapy for any condition for which an opiate would otherwise be prescribed. CA resident? CA resident? Connecticut. CT resident?

Legislation 166

Legislation Decriminalization Access Patients 166

SpeedWeed

SEPTEMBER 9, 2021

In fact, the pharmaceutical infrastructure that faces medical cannabis companies is far from either clear cut or easy to navigate. for example), pharmaceutical drugs may not be advertised directly to potential consumers (also known as patients). All well and good—but this is the good news. . Here is why. Unlike the U.S.

Legalization 52

Legalization Pharmaceutical Patients Extraction 52

The Cannigma

OCTOBER 9, 2021

Varied personal accounts of cannabis consumption causing a wide range of urinary effects have included but are not limited to: being unable to pee while feeling a strong urge to pee, peeing caused by laughter, and multiple sclerosis patients learning their cannabis medication also helps reduce the number of times they have to run to the bathroom.

Cannabinoids 86

Cannabinoids Consumption Patients Cannabis 86

Cannabis Law Report

OCTOBER 13, 2021

Most notably, drug-assisted therapy often improves the patient-therapist relationship and increases flexibility in the patient’s mind, allowing patients to discover and incorporate new ways of addressing their conditions. There is no certainty that any of these events will occur. About Clearmind Medicine Inc.

Medicine 52

Medicine Research and Development Therapy Events 52

Healer

DECEMBER 17, 2021

Drug interactions reported in the scientific literature most often occur at very high doses used in clinical trials of epilepsy and other conditions. Knowing these can allow you or your healthcare provider to look up the metabolism of a pharmaceutical drug and determine if a CBD-drug interaction is possible. topiramate. rufinamide.

CBD 98

CBD THC Conditions Medicine 98

Project CBD

FEBRUARY 28, 2023

5 In June 2018, the FDA approved Epidiolex® (GW Pharmaceuticals; Cambridge, UK), the first FDA-approved pharmaceutical drug to contain a “purified drug substance [CBD] derived from marijuana,” for the treatment of seizures associated with two rare epilepsy disorders. May not be reprinted without permission from the source. 2021.108514.

CBD 144

CBD Seed-To-Sale Food Access 144

Puff Puff Post

SEPTEMBER 16, 2019

16, 2019 /CNW/ – Québec doctors have a new tool at their disposal for learning about medical cannabis and its viability as a treatment option for their patients. “It is our duty as physicians to understand the available treatment options for our patients, and medical cannabis treatments have emerged as an important clinical tool.

Programs 108

Programs Research and Development Education Treatment 108

CannaTech

FEBRUARY 2, 2020

We were not participating in the official WEF events and did not carry the right colored badges to access all of the high profile locations. Instead, we hosted a fully dedicated cannabis lounge under the CannaTech umbrella, our premier cannabis events platform.

Medicine 59

Medicine Events Patients Access 59